Ads
related to: medicine to reduce eosinophil count- Identifying Patients
See The Data Across Patients
With Varying Labs & Triggers.
- Clinical Data Tool
Use This Tool To See Data In
Varying Patient Types
- Asthma Drivers
What Can Multiple Drivers And
Triggers Lead To? Learn More.
- Physician Resources
Access Free Physician Resources
On The Official Site.
- Identifying Patients
Search results
Results From The WOW.Com Content Network
Eosinopenia is a condition where the number of eosinophils, a type of white blood cell, in circulating blood is lower than normal. [1] Eosinophils are a type of granulocyte and consequently from the same cellular lineage as neutrophils, basophils, and mast cells.
Dexpramipexole is a first-in-class oral investigational medicine that lowers blood and tissue eosinophils before they can cause damage in the target organ. Dexpramipexole is being developed by Areteia Therapeutics and has the potential to be the first oral treatment ever approved for eosinophilic asthma.
The benefits with reslizumab are its ability to reduce the exacerbation rate and improve lung function and asthma-related quality of life in patients with severe eosinophilic asthma (with blood eosinophil count ≥ 400 cells/μL) and with at least one previous asthma exacerbation in the preceding year.
This monoclonal antibody –related article is a stub. You can help Wikipedia by expanding it.
Eosinopenia, decrease in eosinophil blood count; Eosinophilia, increase (>500 cells per microliter) in eosinophil blood count; Hypereosinophilia, extreme increase (>1,500 cells per microliter) in eosinophil blood count; Clonal hypereosinophilia, presence of a premalignant or malignant clone of eosinophils in bone marrow and blood
Eosinophilia is a condition in which the eosinophil count in the peripheral blood exceeds 5 × 10 8 /L (500/μL). [1] Hypereosinophilia is an elevation in an individual's circulating blood eosinophil count above 1.5 × 10 9 / L (i.e. 1,500/ μL ).
Ad
related to: medicine to reduce eosinophil count